Celcuity Inc. (NASDAQ:CELC – Get Free Report) has received a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $29.20.
CELC has been the topic of a number of research analyst reports. Craig Hallum reaffirmed a “buy” rating and set a $27.00 price objective (up from $25.00) on shares of Celcuity in a research report on Thursday, May 16th. SVB Leerink initiated coverage on shares of Celcuity in a research report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective on the stock. Leerink Partnrs raised shares of Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Stifel Nicolaus reiterated a “buy” rating and issued a $40.00 target price on shares of Celcuity in a research note on Thursday, May 16th. Finally, Needham & Company LLC reduced their target price on shares of Celcuity from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Friday, May 31st.
Read Our Latest Stock Report on Celcuity
Institutional Trading of Celcuity
Celcuity Stock Performance
Shares of CELC opened at $17.95 on Tuesday. The company’s 50 day moving average price is $16.27 and its 200 day moving average price is $16.63. Celcuity has a 52 week low of $8.39 and a 52 week high of $22.19. The company has a market capitalization of $630.05 million, a PE ratio of -6.46 and a beta of 0.81. The company has a debt-to-equity ratio of 0.28, a quick ratio of 11.23 and a current ratio of 11.23.
Celcuity (NASDAQ:CELC – Get Free Report) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.07. Research analysts expect that Celcuity will post -2.86 EPS for the current fiscal year.
About Celcuity
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Featured Stories
- Five stocks we like better than Celcuity
- What Is WallStreetBets and What Stocks Are They Targeting?
- Survey: Top 175 Fittest Retirement Locations in America
- Stock Analyst Ratings and Canadian Analyst Ratings
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Why Are These Companies Considered Blue Chips?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.